Botanix Pharmaceuticals Limited

CHIA:BOT Stock Report

Market Cap: AU$717.9m

Botanix Pharmaceuticals Future Growth

Future criteria checks 6/6

Botanix Pharmaceuticals is forecast to grow earnings and revenue by 99.4% and 77.6% per annum respectively. EPS is expected to grow by 102.1% per annum. Return on equity is forecast to be 54.4% in 3 years.

Key information

99.4%

Earnings growth rate

102.1%

EPS growth rate

Pharmaceuticals earnings growth37.0%
Revenue growth rate77.6%
Future return on equity54.4%
Analyst coverage

Low

Last updated11 Sep 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

CHIA:BOT - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2027201110100951
6/30/20261053420181
6/30/2025364-7-71
6/30/20242-14-26-8N/A
3/31/20241-12-26-9N/A
12/31/20230-10-27-10N/A
9/30/20232-10-23-11N/A
6/30/20234-9-19-12N/A
3/31/20235-10-20-12N/A
12/31/20226-11-20-12N/A
9/30/20225-12-17-12N/A
6/30/20223-13-14-11N/A
3/31/20221-12-8-7N/A
12/31/20210-11-2-2N/A
9/30/20213-7-3-3N/A
6/30/20217-3-3-3N/A
3/31/20217-6-6-6N/A
12/31/20207-9-8-8N/A
9/30/20207-13-13-13N/A
6/30/20208-17-17-17N/A
3/31/20208-18-21-21N/A
12/31/20198-20-24-24N/A
9/30/20196-18-19-19N/A
6/30/20195-17-13-13N/A
3/31/20195-15-12-12N/A
12/31/20185-13-10-10N/A
9/30/20183-12-10-10N/A
6/30/20182-11-10-10N/A
3/31/20182-8N/A-8N/A
12/31/20172-6N/A-7N/A
9/30/20171-5N/A-6N/A
6/30/2017N/A-5N/A-5N/A
12/31/2016N/A-3N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BOT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: BOT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BOT is expected to become profitable in the next 3 years.

Revenue vs Market: BOT's revenue (77.6% per year) is forecast to grow faster than the Australian market (5.9% per year).

High Growth Revenue: BOT's revenue (77.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BOT's Return on Equity is forecast to be very high in 3 years time (54.4%).


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 02:42
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Botanix Pharmaceuticals Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter